Conference Reports for NATAP

The Liver Meeting Digital Experience AASLD Washington on 04-08 November 2022 Back

HCC Risk in HCV After SVR in Cirrhosis or No Cirrhosis       Post HCV DAA Treatment Cure HCC Surveillance is NOT BEING DONE & likely contributes significantly to HCC. Jules Levin, NATAP   AASLD: Hepatocellular Carcinoma: State of the Art - missing is & Post HCV Cure Surveillance in Patients with Cirrhosis ! - (11/21/22)   we see a rising mortality rate in men & women, one of the few cancers in which we see this. If these trends continue HCC is projected to be 3rd leading cause of death by 2035.   AASLD: Risk factor of hepatocellular carcinoma occurrence after sustained virologic responses in hepatitis C virus patients without advanced liver fibrosis - (11/14/22)   AASLD: The impact of direct-acting antiviral treatment for HCV on hepatocellular carcinoma risk in a large population-based cohort study - (11/17/22) AASLD: Increasing time since eradication of HCV is independently associated with a lower risk of HCC - (11/09/22) AASLD: 67% Remain Untreated - Burden of Illness Associated with Remaining Untreated Following a Diagnosis of Chronic Hepatitis C Virus - (11/08/22)